Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers consumer health 7% first quarter growth led by worldwide analgesic sales.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS OTC, NUTRITIONAL SALES INCREASE IN FIRST QUARTER by 7% and 12%, respectively, compared to worldwide sales for the same period in 1996, the company reported April 22. Growth in the nonprescription drugs arena was due in part to increased volume of worldwide analgesic sales, including Efferalgan effervescent acetaminophen (up 17% to $47 mil.), Dafalgan acetaminophen and Aspirin UPSA effervescent aspirin, Bristol-Myers Squibb said. The products, part of BMS' 1994 acquisition of the French manufacturer UPSA, have grown steadily under Bristol-Myers ("The Tan Sheet" Sept. 26 1994, p.15).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel